EU: HORIZON2020 Call – Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
Vaccines and monoclonal Antibodies (mAb) may reduce antimicrobial resistance (AMR). However, individual vaccine developers and manufacturers, as well as organisations developing mAbs and health authorities, acting alone, do not have the resources and the full expertise required to make a realistic and comparable assessment of the use of the different products on the reduction of AMR. This could instead be possible through the development of a mathematical model. For such a model to be representative of the concerns and interests of the various actors (i.e. industry and the public health sector), it should take into account the perspectives of these different actors in order to capture all relevant impacts both in terms of costs and health outcomes.
1) Evaluate the burden of disease of AMR by estimating inpatients’ (acute care hospitals and long-term care facilities) and outpatients’ infection rates in at least 8 EU countries for which suitable data is collected and available, as well as in the US , and the relative attributable risk for morbidity, mortality and costs.
2) Build a comprehensive AMR model (i.e. model structure, parameters, assumptions) based on an analysis of the strengths and weaknesses of existing models, and a gap analysis.
3) Collecting, gathering, and analysing data from existing databases to feed the model.
4) Develop and test a cost-effectiveness analysis (CEA) to estimate the cost and benefits of covering defined target groups (e.g. 18+, 60+, surgeries) with mAbs and vaccines.
5) Set up a study to test, monitor, evaluate and improve the model.
6) Ensure a public and broad access to the model
KEY DATES & APPLICATION:
Opening:23 June 2020
Deadline:29 September 2020 (17:00:00 Brussels time)
2nd stage Deadline:17 March 2021 (17:00:00 Brussels time)
More information available here